Therefore, targeting oncogenes such as TWIST1 in malignant clonal cells could potentially improve therapeutic strategies by remodeling the BMME in the treatment of MDS/AML and other hematopoietic malignancies. Here, TWIST1 is linked to myelodysplastic syndrome.